X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (26) 26
aged (21) 21
humans (21) 21
female (20) 20
male (20) 20
index medicus (19) 19
middle aged (19) 19
adult (18) 18
chemotherapy (17) 17
cancer (12) 12
gastric cancer (12) 12
stomach cancer (11) 11
care and treatment (10) 10
analysis (9) 9
colorectal neoplasms - drug therapy (9) 9
retrospective studies (9) 9
tumors (9) 9
aged, 80 and over (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cancer patients (8) 8
colorectal cancer (8) 8
double-blind (8) 8
fluorouracil (8) 8
medicine & public health (8) 8
metastasis (8) 8
disease-free survival (7) 7
kaplan-meier estimate (7) 7
prognosis (7) 7
treatment outcome (7) 7
antimitotic agents (6) 6
antineoplastic agents (6) 6
bevacizumab (6) 6
cancer research (6) 6
colorectal neoplasms - pathology (6) 6
drug therapy (6) 6
leucovorin (6) 6
neoplasm staging (6) 6
patients (6) 6
research (6) 6
stomach neoplasms - pathology (6) 6
1st-line treatment (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
cancer therapies (5) 5
gastroenterology (5) 5
gastroenterology & hepatology (5) 5
mutation (5) 5
stomach neoplasms - drug therapy (5) 5
abdominal surgery (4) 4
antibodies, monoclonal - adverse effects (4) 4
cetuximab (4) 4
clinical trials (4) 4
colorectal neoplasms - mortality (4) 4
dose-response relationship, drug (4) 4
metastases (4) 4
monoclonal antibodies (4) 4
multicenter (4) 4
neoplasm metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
nivolumab (4) 4
stomach neoplasms - mortality (4) 4
surgical oncology (4) 4
survival (4) 4
adenocarcinoma (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
biopsy (3) 3
blockade (3) 3
combination (3) 3
complications and side effects (3) 3
dosage and administration (3) 3
drug combinations (3) 3
electrotherapy (3) 3
fluorouracil - therapeutic use (3) 3
follow-up studies (3) 3
gastroenterology and hepatology (3) 3
gene amplification (3) 3
gene expression (3) 3
genes (3) 3
health aspects (3) 3
hematology, oncology and palliative medicine (3) 3
human necessities (3) 3
hygiene (3) 3
immunohistochemistry (3) 3
leucovorin - therapeutic use (3) 3
magnetotherapy (3) 3
medical or veterinary science (3) 3
medical prognosis (3) 3
organoplatinum compounds - therapeutic use (3) 3
oxaliplatin (3) 3
paclitaxel (3) 3
preparations for medical, dental, or toilet purposes (3) 3
proteins (3) 3
radiation therapy (3) 3
receptor, erbb-2 - genetics (3) 3
regorafenib (3) 3
research article (3) 3
safety (3) 3
solid tumors (3) 3
stomach neoplasms - genetics (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Introduction Recently, promising efficacy has been reported for cell therapies using chimeric antigen receptor (CAR)-T cells, and bispecific T-cell... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Talazoparib is a potent, orally bioavailable, small molecule poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor. The... 
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Current Colorectal Cancer Reports, ISSN 1556-3790, 12/2016, Volume 12, Issue 6, pp. 289 - 295
In Japan, adjuvant chemotherapy for colon cancer was mainly developed using oral fluoropyrimidines. However, all Japanese studies to date have failed to... 
IDEA collaboration | Adjuvant chemotherapy | Colon cancer | Japan, oral fluoropyrimidine | Oncotype DX® Colon Cancer Assay | Medicine & Public Health | Colorectal Surgery | Oncology | Japanese guideline | Multigene assay | Proctology | Task forces | Pyrimidines | Adjuvant treatment | Clinical trials | Practice guidelines (Medicine) | Health aspects | Cancer
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Nivolumab (NIVO) showed a survival benefit compared to placebo in patients (pts) with advanced gastric cancer (AGC) after two or more... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Pembro is approved for microsatellite instability-high (MSI-H)/dMMR CRC that has progressed on fluoropyrimidine+oxaliplatin+irinotecan... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.